Addex Therapeutics Ltd (ADXN)
17.95
-1.33
(-6.90%)
USD |
NASDAQ |
Apr 23, 11:33
Addex Therapeutics Cash from Operations (TTM): -8.901M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -8.901M |
| September 30, 2023 | -11.74M |
| June 30, 2023 | -11.87M |
| March 31, 2023 | -14.54M |
| December 31, 2022 | -17.23M |
| September 30, 2022 | -17.12M |
| June 30, 2022 | -17.03M |
| March 31, 2022 | -18.27M |
| December 31, 2021 | -16.09M |
| Date | Value |
|---|---|
| September 30, 2021 | -11.79M |
| June 30, 2021 | -12.40M |
| March 31, 2021 | -11.75M |
| December 31, 2020 | -12.99M |
| September 30, 2020 | -13.91M |
| June 30, 2020 | -15.66M |
| March 31, 2020 | -11.29M |
| December 31, 2019 | -9.544M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-18.27M
Minimum
Mar 2022
-8.901M
Maximum
Dec 2023
-13.65M
Average
-12.99M
Median
Dec 2020
Cash from Operations (TTM) Benchmarks
| AC Immune SA | -67.27M |
| CRISPR Therapeutics AG | -260.38M |
| NLS Pharmaceutics Ltd | -13.51M |
| Molecular Partners AG | -65.71M |
| MoonLake Immunotherapeutics | -42.78M |